American Society of Plastic Surgeons
For Medical Professionals

Study Urges Gene Testing Before Breast Reconstruction Using Abdominal Tissue

For women with breast cancer who opt for breast reconstruction using a tissue flap from the abdomen, gene testing for high-risk mutations should be performed before surgery, concludes a report in the July issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Although only a small percentage of patients will test positive for BRCA or other high-risk mutations, genetic testing should be considered for all women in whom unilateral (single) mastectomy and abdominal-based free-flap breast reconstruction (FFBR) is planned, according to the study by Erez Dayan, MD, of Brigham & Women’s Hospital/Harvard Medical School and colleagues.

Genetic Testing Before FFBR Lowers Costs, Avoids Repeated Surgery

The study included 160 women with breast cancer who underwent single (unilateral) mastectomy followed by abdominal-based tissue breast reconstruction between 2007 and 2016. This approach to breast reconstruction uses a flap of tissue from the patient's abdomen. Some women choose this autologous reconstruction approach, rather than implant-based breast reconstruction.

Based on a personal or family history of breast cancer, 111 women met guidelines for genetic testing before mastectomy and breast reconstruction. For women with BRCA mutations, breast cancer risk is approximately five times higher than in women without a mutation. Some of these high-risk women will undergo "preventive" mastectomy to reduce their risk of breast cancer.

In the study, only about 56 percent of patients who met criteria for genetic testing were actually tested. Testing was also performed in 10 percent of women who did not meet criteria.

At an average follow-up of about six years, three patients developed cancer of the opposite breast. All three of these women proved to have a high-risk mutation that could have been detected by genetic testing before surgery.

Thus in the total experience of 160 patients, 1.9 percent were diagnosed with harmful mutations after reconstruction, which led to a second mastectomy and reconstruction. "These subsequent cancers resulted in additional surgeries after the patients had completed multi-staged reconstructions, carrying psychosocial and financial burdens for patients and increased costs for the healthcare system," Dr. Dayan comments.

If the women had known they were at high risk, they might have chosen to undergo risk-reducing mastectomy and reconstruction. That's especially important before abdominal-based tissue breast reconstruction because the abdominal donor site can only be used once.

The researchers also looked at the cost-effectiveness of expanding genetic testing for breast cancer. While testing all patients would have increased costs, it would have avoided the additional costs of treating the second cancers, reducing total costs by about $260,000. Dr. Dayan and co-authors note that insurance companies sometimes deny coverage for genetic testing for breast cancer risk, but that the costs of testing have decreased in recent years.

The study "supports the notion that genetic testing should be offered to all patients for whom unilateral abdominal-based tissue breast reconstruction is planned," Dr. Dayan and colleagues conclude. "Plastic surgeons should take an active role in discussing with patients and their care providers the implications of genetic testing in these cases."

Plastic and Reconstructive Surgery Editor-in-Chief Rod J. Rohrich, MD, agrees with the recommendation to test for high-risk gene mutations before surgery with breast reconstruction using an abdominal tissue flap. In a video commentary, he states, "Not having genetic testing has serious implications: it puts women at risk for future cancers, leaves family members unaware, and limits future reconstructive options."

Plastic and Reconstructive Surgery® is published by Wolters Kluwer.

Click here to read "Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction"

Article: "Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction" (doi: 10.1097/PRS.0000000000005693)

About Plastic and Reconstructive Surgery

For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPS

The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 8,000 member surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 93 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.


Patient Care Center